Correction of first trimester biochemical aneuploidy screening markers for smoking status: Influence of gestational age, maternal ethnicity and cigarette dosage

Prenatal Diagnosis

Volumn 33, Issue 2, 2013, Pages 116-123

  Spencer, Kevin ^a   Cowans, Nicholas J ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; ANEUPLOIDY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ETHNICITY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SMOKING; PRENATAL SCREENING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; ENGLAND; FEMALE; GESTATIONAL AGE; HUMANS; MASS SCREENING; MIDDLE AGED; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; REFERENCE STANDARDS; REFERENCE VALUES; SMOKING; YOUNG ADULT;

EID: 84873262194     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4017     Document Type: Article

References (31)

1. Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376-83.
2. Wright D, Spencer K, Kagan KK, et al. First-trimester combined screening for trisomy 21 at 7-14weeks' gestation. Ultrasound Obstet Gynecol 2010;36:404-11.
3. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
4. Nicolaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221-6.
5. Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10-14weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7.
6. Kagan KO, Wright D, Spencer K, et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008;31:493-502.
7. Kagan KO, Frisova V, Nicolaides KH, Spencer K. Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6weeks of gestation. Prenat Diagn 2007;27:849-53.
8. Spencer K. The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy. Prenat Diagn 1999;19:1065-6.
9. Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 2004;24:169-73.
10. Ball S, Ekelund C, Wright D, et al. Temporal effects of maternal and pregnancy characteristics on serum PAPP-A and free beta-hCG at 7-14weeks' gestation. Ultrasound Obstet Gynecol 2012. DOI: 10.1002/uog.11209.
11. Spencer K, Spencer CE, Power M, et al. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. BJOG 2000;107:1271-5.
12. Spencer K, Spencer CE, Power M, et al. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-6.
13. Demir R, Demir AY, Yinanc M. Structural changes in placental barrier of smoking mother. A quantitative and ultrastructural study. Pathol Res Pract 1994;190:656-67.
14. Jauniaux E, Burton GJ. Morphological and biological effects of maternal exposure to tobacco smoke on the feto-placental unit. Early Hum Dev 2007;83:699-706.
15. Burton GJ, Palmer ME, Dalton KJ. Morphometric differences between the placental vasculature of non-smokers, smokers and ex-smokers. Br J Obstet Gynaecol 1989;96:907-15.
16. Ball S, Wright D, Sodre D, et al. Temporal effect of Afro-Caribbean race on serum pregnancy-associated plasma protein-a at 9-13weeks' gestation in screening for aneuploidies. Fetal Diagn Ther 2012;31:162-9.
17. Vadiveloo T. Sequential testing strategies in prenatal screening for down's syndrome (thesis), 2009. http://theses.gla.ac.uk/1889/01/2009ThenmalarPhD.pdf.
18. Spencer K. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 1998;18:225-34.
19. Tobacco use among minority ethnic populations and cessation interventions. http://www.healthcare-today.co.uk/doclibrary/documents/pdf/639_tobacco_use_minority.pdf [Accessed on Sep 2012].
20. Smoking statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/smoking/lung-cancer-and-smoking-statistics [Accessed on Sep 2012].
21. Wagenknecht LE, Cutter GR, Haley NJ, et al. Racial differences in serum cotinine levels among smokers in the Coronary Artery Risk Development in (Young) Adults study. Am J Public Health 1990;80:1053-6.
22. Pattishall EN, Strope GL, Etzel RA, et al. Serum cotinine as a measure of tobacco smoke exposure in children. Am J Dis Child 1985;139:1101-4.
23. Henningfield JE. Can genetic constitution affect the 'objective' diagnosis of nicotine dependence? Am J Public Health 1990;80:1040-1.
24. McCarthy WJ, Caskey NH, Jarvik ME. Ethnic differences in nicotine exposure. Am J Public Health 1992;82:1171-3.
25. Satariano WA, Swanson GM. Racial differences in cancer incidence: the significance of age-specific patterns. Cancer 1988;62:2640-53.
26. Perez-Stable EJ, Herrera B, Jacob P, III, Benowitz NL. Nicotine metabolism and intake in black and white smokers. JAMA 1998;280:152-6.
27. Caraballo RS, Giovino GA, Pechacek TF, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA 1998;280:135-9.
28. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P, III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002;94:108-15.
29. Nakajima M, Fukami T, Yamanaka H, et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006;80:282-97.
30. Shipton D, Tappin DM, Vadiveloo T, et al. Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional study. BMJ 2009;339:b4347-55.
31. Benowitz NL, Bernert JT, Caraballo RS, et al. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 2009;169:236-48.